Diagnosis of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
The diagnosis of ATTR-CM is often delayed or missed, resulting in an underdiagnosed* cause of heart failure with preserved ejection fraction (HFpEF).1,2
*In two studies, wild-type ATTR deposits were identified in the hearts of 13–17% of older patients with HFpEF.1,2
In an ex-US study of 120 HFpEF patients 60 years or older, wild-type ATTR was confirmed in 13% (13.3%; 95% CI: 7.2–19.5) of the patients1
In a US study of 441 autopsied patients, 109 of whom had HFpEF, cardiac wild-type ATTR deposits were found in 17% of the patients2
"By clicking "confirm" to create an account, you confirm that the information you have provided above is correct, and you agree to (i) Pfizer’s processing of your personal data, including its transfer internationally and to third parties, in accordance with the Pfizer Privacy and Cookie Policy; and (ii) Pfizer’s Website Terms of Use."